Tackling dipeptidyl peptidase IV in neurological disorders
- Publication Type:
- Journal Article
- Neural Regeneration Research, 2018, 13 (1), pp. 26 - 34
- Issue Date:
Files in This Item:
|Tackling Dipeptidyl Peptidase IV in Neurological Disorders.pdf||Published Version||322.15 kB|
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
© 2018, Medknow Publications. All rights reserved. Dipeptidyl peptidase IV (DPP-IV) is a serine protease best known for its role in inactivating glucagon-like peptide-1 (GLP-1), pituitary adenylate cyclase-activating polypeptide (PACAP) and glucose-dependent insulinotropic peptide (GIP), three stimulators of pancreatic insulin secretion with beneficial effects on glucose disposal. Owing to the relationship between DPP-IV and these peptides, inhibition of DPP-IV enzyme activity is considered as an attractive treatment option for diabetic patients. Nonetheless, increasing studies support the idea that DPP-IV might also be involved in the development of neurological disorders with a neuroinflammatory component, potentially through its non-incretin activities on immune cells. In this review article, we aim at highlighting recent literature describing the therapeutic value of DPP-IV inhibitors for the treatment of such neurological conditions. Finally, we will illustrate some of the promising results obtained using berberine, a plant extract with potent inhibitory activity on DPP-IV.
Please use this identifier to cite or link to this item: